MichelNgNP(He/Him)

PubMed

• 35 citations
  Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response.
  Kian Bichoupan, Valérie Martel-Laferrière, David H. Sachs, Michel Ng, Emily A. Schonfeld
  Hepatology. 2014-10-01
• 52 citations
  Telaprevir in the Treatment of Acute Hepatitis C Virus Infection in HIV-Infected Men
  Daniel S. Fierer, Douglas T. Dieterich, Michael P. Mullen, Andrea D. Branch, Alison J. Uriel
  Clinical Infectious Diseases. 2014-03-15
• 3 citations
  Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results.
  Kian Bichoupan, Neeta Tandon, James F. Crismale, Joshua Hartman, David Del Bello
  World Journal of Virology. 2017-11-12

Journal Articles

• A 50 Year Old Male with Cirrhosis, History of Alcohol Use Disorder, and Unexpected Decline while on Direct Acting Antiviral Therapy for Hepatitis C  
  Ng M, Patel A, Martel-Laferriere V, Perumalswami P, Psychiatric Annals, 1/1/2013

Abstracts/Posters

• Among HCV-infected Patients on triple therapy, serum calcium is a new indicator of treatment response.
  Bichoupan K, Martel-Laferriere V, Pappas A, Schonfeld E, Ng M, Sefcik R, Vachon ML, Standen M, Perumalswami P, Schiano TD, Odin JA, Liu L, Dieterich DT, Branch AD, 8th Annual American Physician Scientists Association in Chicago, 1/1/2012
• Effectiveness of HCV triple therapy in New York City.
  Martel-Laferrière V, Bichoupan K, Pappas A, Schonfeld E, Ng M, Sefcik R, Vachon ML, Standen M, Perumalswami P, Schiano TD, Odin JA, Liu L, Dieterich DT, Branch AD, European Association for the Study of Liver (EASL), The International Liver Congress 2012, 47th Annual Meeting, Barcelona, Spain, 1/1/2012
• Among HCV-infected patients on triple therapy, serum calcium is a new indicator of treatment response.
  Bichoupan K, Martel-Laferrière V, Pappas A, Schonfeld E, Ng M, Standen M, Sefcik R, Vachon ML, Perumalswami P, Schiano T, Odin J, Liu L, Dieterich D, Branch A, International Association of Physicians in AIDS Care (IAPAC), 2nd International Conference on Viral Hepatitis, New York, NY, 1/1/2012
• Early on-treatment responses to TVR do not differ between HIV/HCV co-infected and HCV mono-infected patients.
  Martel-Laferriere V, Bichoupan K, Pappas A, Schonfeld E, Stivala A, Vachon ML, Ng M, Standen M, Dieterich D, Branch A, 19th Conference on Retrovirus and Opportunistic Infections (CROI), Seattle, WA, 1/1/2012
• Effectiveness of telaprevir in HIV/HCV co-infected patients.
  Martel-Laferriere V, Bichoupan K, Pappas A, Schonfeld E, Ng Michel, Standen M, Sefcik R, Vachon ML, Perumalswami P, Schiano T, Odin J, Liu L, Dieterich D, Branch A, International Association of Physicians in AIDS Care (IAPAC), 2nd International Conference on Viral Hepatitis, New York, NY, 1/1/2012
• Join now to see all

Lectures

• National Hepatitis B & C: Training Program and Treatment Update. 
  New York, NY - 1/1/2013
• "Vodka as a Tonic for Victrelis: A Tale of Addiction and Advanced HCV" 
  Mount Sinai School of Medicine - 1/1/2013
• "Decompensated Cirrhosis and Protease Inhibitors" 
  Mount Sinai School of Medicine - 1/1/2013
• "A New Era in the Treatment of Hepatitis C" 
  1/1/2012
• Delivering HCV Care: NP/PA Perspectives in the Management of Hepatitis C. 
  New York, NY - 1/1/2012
• Cases on Hepatitis (B/C/D) and HIV: The Rise of Tenofovir Mutants? 
  Mount Sinai School of Medicine - 1/1/2012
• Drug-Drug Interactions with Direct Acting Antiviral Treatments for Hepatitis C. 
  Mount Sinai School of Medicine - 1/1/2012
• HCV Practice Management Tips. 
  Mount Sinai School of Medicine - 1/1/2011
• Pregnancy and Hepatitis C: A Case Presentation. 
  Mount Sinai School of Medicine - 1/1/2011
• Join now to see all